Dr. Wael S. Abo-auda, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,935
Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license N3413 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White the Heart Hospital Plano Plano, TX
- Texoma Medical Center Denison, TX
- Baylor Scott and White Surgical Hospital at Sherma Sherman, TX
- Alliancehealth Durant Durant, OK
- Baylor Scott and White the Heart Hospital Corinth Denton, TX
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,935
- Services billed
- 18,712
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 5,166 | 375 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 3,011 | 384 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 2,581 | 383 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,813 | 686 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,304 | 762 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 1,000 | 897 |
| Ultrasound of both sides of head and neck blood flow | 405 | 364 |
| Ct scan of blood vessels and grafts of heart with contrast | 333 | 329 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 328 | 159 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 295 | 268 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Mckinney, TX | 893 |
| Atorvastatin Calcium Other prescribers in Mckinney, TX | 871 |
| Eliquis (apixaban) Other prescribers in Mckinney, TX | 569 |
| Metoprolol Tartrate Other prescribers in Mckinney, TX | 547 |
| Carvedilol Other prescribers in Mckinney, TX | 444 |
| Losartan Potassium Other prescribers in Mckinney, TX | 421 |
| Lisinopril Other prescribers in Mckinney, TX | 356 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Mckinney, TX | 348 |
| Furosemide Other prescribers in Mckinney, TX | 320 |
| Amlodipine Besylate Other prescribers in Mckinney, TX | 261 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 47 payments worth $1,104 in total to this clinician.
| Heartflow, Inc. | $154 |
|---|---|
| Merck Sharp & Dohme LLC | $135 |
| Cleerly, Inc. | $124 |
| Novo Nordisk Inc | $108 |
| Stryker Corporation | $77.91 |
| Bayer HealthCare Pharmaceuticals Inc. | $73.38 |
| Impulse Dynamics (USA) Inc. | $54.07 |
| Abbott Laboratories | $47.40 |
| Food and Beverage | $1,064 |
|---|---|
| Education | $40.44 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Aug 21, 2025 | Education Kerendia · Cardio-Renal · in-kind | $20.22 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 21, 2025 | Education Kerendia · Cardio-Renal · in-kind | $20.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $99,453 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
Janssen Research & Development, LLC - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - Study name not reported
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.